A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
24actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-02 | actual | When the study began enrolling |
| Primary completion | 2026-03-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-23 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ABBV-8736
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs)
measured Up to Approximately 113 Days
Maximum Observed Concentration (Cmax) of ABBV-8736
measured Up to Approximately 113 Days
Time to Cmax (Tmax) of ABBV-8736
measured Up to Approximately 113 Days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of ABBV-8736
measured Up to Approximately 113 Days
Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-8736
measured Up to Approximately 113 Days
Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-8736
measured Up to Approximately 113 Days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-8736
measured Up to Approximately 113 Days
Clearance (CL) for Intravenous (IV) Dosing
measured Up to Approximately 113 Days
Immunogenicity of ABBV-8736 as Determined by Anti-Drug Antibodies (ADAs)
measured Up to Approximately 113 Days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed